Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

The key role of RAASi therapy in patients with HF

10' education - Sep. 26, 2023 - Shelley Zieroth, MD

Treating hyperkalemia in patients with HF

10' education - Sep. 26, 2023 - Mikhail Kosiborod, MD

Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF

10' education - Sep. 26, 2023 - Aaron Wong, MD

Healthy lifestyle interventions for CVD risk reduction in secondary prevention

3' education - Sep. 25, 2023 - Ruxandra Maria Christodorescu, MD and Nadia Bonekamp, MD

Study with traditional Chinese medicine in HFrEF: what's the next step?

3' education - Sep. 21, 2023 - Joseph Wu, MD, PhD

Artificial intelligence for the management of HF

3' education - Sep. 14, 2023 - Folkert Asselbergs, MD, PhD & Pascal Burger, MD

A pragmatic trial of natriuresis-guided use of loop diuretics in acute HF

3' education - Sep. 11, 2023 - Kevin Damman, MD, PhD

Update of ESC guidelines on heart failure in a nutshell

5' education - Sep. 4, 2023 - Theresa McDonagh, MD

Main messages of new ESC guidelines for CVD management in diabetes

3' education - Aug. 29, 2023 - Nikolaus Marx, MD

High intensity treatment with optimal neurohormonal blockade facilitates better decongestion in acute HF

3' education - Aug. 28, 2023 - Piotr Ponikowski, MD, PhD

Unique randomized withdrawal heart failure trial with SGLT2 inhibitor

3' education - Aug. 26, 2023 - Milton Packer, MD

Protective renal effects of ARNI in patients with HFmrEF/HFpEF

3' education - Aug. 26, 2023 - Muthiah Vaduganathan, MD

Clinically meaningful benefits with GLP-1RA in HFpEF and obesity

3' education - Aug. 25, 2023 - Mikhail Kosiborod, MD

What to do if potassium levels increase in HF?

10' education - Aug. 7, 2023 - Mikhail Kosiborod, MD

Practical experience and model for optimizing RAASi-based therapy in HF

10' education - July 25, 2023 - Aaron Wong, MD

Applying evidence to practice: What can we learn from recent clinical trials of IV iron use in HF?

10' education - July 13, 2023 - Piotr Ponikowski, MD, PhD and Robert J. Mentz, MD

Hyperkalemia: Is it still a challenge in 2023?

10' education - July 11, 2023 - Ileana L. Piña, MD, Javed Butler, MD, and Patrick Rossignol, MD, PhD

Continuing foundational therapy in symptomatic HF: the key role of RAASi-based therapy

10' education - July 6, 2023 - Shelley Zieroth, MD

Recognizing HCM and HF: making the diagnosis

10' education - June 12, 2023 - Mariana Brandão, MD

HCM and heart failure: is your patient at risk?

10' education - June 9, 2023 - Rudolf de Boer, MD, PhD

Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial

3' education - June 1, 2023 - Ahmad Masri, MD

Benefits of rapid uptitration of HF medications independent of baseline renal function

3' education - May 30, 2023 - Jozine ter Maaten, MD, PhD

Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF

3' education - May 30, 2023 - Jasper Brugts, MD, PhD

ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF

3' education - May 25, 2023 - Robert Mentz, MD

Maintaining GDMT while lowering potassium in heart failure

10' education - Mar. 27, 2023 - Javed Butler, MD, Ileana L. Piña, MD, and Patrick Rossignol, MD, PhD

Well-designed EHR tools can improve prescribing of MRA in HFrEF

3' education - Mar. 21, 2023 - Amrita Mukhopadhyay, MD

Early eGFR decline after transitioning to ARNI not associated with adverse outcomes

3' education - Mar. 6, 2023 - Safia Chatur, MD

Protective cardiac effects of statin in patients with lymphoma treated with anthracyclines

3' education - Mar. 5, 2023 - Prof. Marielle Scherrer-Crosbie, MD, PhD

Revascularization in cardiac surgery

10' education - Feb. 28, 2023 - Lauren Barron, MD, Navin Kapur, MD, Adam DeVore, MD

Revascularization in high-risk PCI patients

10' education - Feb. 28, 2023 - Navin Kapur, MD, Adam DeVore, MD, Lauren Barron, MD,

The key role of RAASi therapy in patients with HF

10' education - Sep. 26, 2023 - Shelley Zieroth, MD
Shelley Zieroth talks about the importance of continuing foundational therapy in symptomatic HF, despite challenges such as the occurrence of hyperkalemia.

Shelley Zieroth talks about the importance of continuing foundational therapy in symptomatic HF, despite challenges such as the occurrence of hyperkalemia.

Treating hyperkalemia in patients with HF

10' education - Sep. 26, 2023 - Mikhail Kosiborod, MD
What to do when hyperkalemia occurs in patients with HF? Mikhail Kosiborod discusses the treatment options, and focuses on how novel potassium binders may enable optimizing the use and dosing of RAASi therapy in HF.

What to do when hyperkalemia occurs in patients with HF? Mikhail Kosiborod discusses the treatment options, and focuses on how novel potassium binders may enable optimizing the use and dosing of RAASi therapy in HF.

Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF

10' education - Sep. 26, 2023 - Aaron Wong, MD
Hyperkalemia is a predictable, treatable, and manageable condition, according to Aaron Wong. He shares his practical experience to manage the risk of hyperkalemia using a novel potassium binder, which allows for the optimization of RAASi therapy in HF.

Hyperkalemia is a predictable, treatable, and manageable condition, according to Aaron Wong. He shares his practical experience to manage the risk of hyperkalemia using a novel potassium binder, which allows for the optimization of RAASi therapy in HF.

GLP-1RA effective in obesity phenotype of HFpEF, regardless of obesity class

Literature - Sep. 25, 2023 - Borlaug BA, et al. - Nat Med. 2023

In a prespecified analysis of the STEP-HFpEF trial among patients with the obesity phenotype of HFpEF, semaglutide reduced body weight and HF-related symptoms and signs compared with placebo across all 3 obesity categories.

Healthy lifestyle interventions for CVD risk reduction in secondary prevention

3' education - Sep. 25, 2023 - Ruxandra Maria Christodorescu, MD and Nadia Bonekamp, MD
**ESC Congress 2023** How do healthy lifestyle interventions fit in the current therapeutic landscape for patients with established CVD? Nadia Bonekamp interviews Ruxandra Maria Christodorescu about this topic.

ESC Congress 2023 How do healthy lifestyle interventions fit in the current therapeutic landscape for patients with established CVD? Nadia Bonekamp interviews Ruxandra Maria Christodorescu about this topic.

Global association of the PURE healthy diet score with health outcomes

Literature - Sep. 21, 2023 - Mente A et al. - Eur Heart J. 2023
Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.

Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.

Study with traditional Chinese medicine in HFrEF: what's the next step?

3' education - Sep. 21, 2023 - Joseph Wu, MD, PhD
**ESC Congress 2023** In the QUEST study, the effect of qiliqiangxin was investigated in patients with HFrEF. Dr. Joseph Wu, president of the American Heart Association, shares his thoughts on the study and discusses which further studies are necessary.

ESC Congress 2023 In the QUEST study, the effect of qiliqiangxin was investigated in patients with HFrEF. Dr. Joseph Wu, president of the American Heart Association, shares his thoughts on the study and discusses which further studies are necessary.

Consistent benefit of SGLT2 inhibitors on CV outcomes across various patient populations

Literature - Sep. 21, 2023 - Usman MS, et al. - J Am Coll Cardiol. 2023

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

Higher circulating levels of EPA, but not DHA, associated with lower MACE risk

Literature - Sep. 18, 2023 - Le VT, et al - Front Cardiovasc Med. 2023

In an observational cohort study, higher plasma levels of eicosapentaenoic acid (EPA), but not docosahexaenoic acid (DHA), were associated with a lower 10-year risk of MACE. Adjustment for DHA level increased the protective effect of higher EPA levels.

Artificial intelligence for the management of HF

3' education - Sep. 14, 2023 - Folkert Asselbergs, MD, PhD & Pascal Burger, MD
**ESC Congress 2023** The diagnosis and management of patients with HF is getting more complex with the vast amount of information available for clinicians. Folkert Asselbergs shares his view on the use of artificial intelligence (AI) in clinical practice.

ESC Congress 2023 The diagnosis and management of patients with HF is getting more complex with the vast amount of information available for clinicians. Folkert Asselbergs shares his view on the use of artificial intelligence (AI) in clinical practice.

Acetazolamide increases successful decongestion in acute decompensated HF irrespective of baseline renal function

News - Sep. 11, 2023

ESC Congress 2023 A prespecified analysis of the ADVOR trial showed that the addition of acetazolamide to loop diuretics increases successful decongestion in patients with acute decompensated HF compared with placebo regardless of baseline renal function.

A pragmatic trial of natriuresis-guided use of loop diuretics in acute HF

3' education - Sep. 11, 2023 - Kevin Damman, MD, PhD
A one-size-fits-all approach is used with regard to loop diuretic therapy in patients with acute HF, although guidelines highlight the importance of early diuresis. Does a natriuresis-guided approach for use of diuretics improve outcomes?

ESC Congress 2023 A one-size-fits-all approach is used with regard to loop diuretic therapy in patients with acute HF, although guidelines highlight the importance of early diuresis. Does a natriuresis-guided approach for use of diuretics improve outcomes?